Fresh Tracks Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Fresh Tracks Therapeutics has terminated its exclusive license agreement with Carna Biosciences, effective March 1, 2024, ending their collaboration on STING inhibitors.
Fresh Tracks Therapeutics' stockholders did not approve the proposed plan of liquidation and dissolution at a special meeting held on February 15, 2024.